Low-Intermediate Risk B-Cell Pts [clinicaltrials_resource:NCT00001586/group/E2]
Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered.
Reported events for NCT00001586 [clinicaltrials_resource:7ef21eda8a20b9a5c6058002b6875633]Total, other adverse events for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/21/count/42]Hemorrhage, GI::Oral cavity for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/22/count/44]Hemorrhage, pulmonary/upper respiratory: Nose for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/23/count/46]Transfusion for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/24/count/48]Hemoptysis for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/25/count/50]Leukocytes (total WBC) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/26/count/52]Lymphopenia for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/27/count/54]Neutrophils/granulocytes (ANC/AGC) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/28/count/56]PTT (Partial Thromboplastin Time) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/29/count/58]Platelets for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/30/count/60]Thrombotic microangiopathy for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/31/count/62]Cardiac arrhythmia - Other, Specify, unknown for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/32/count/64]Pain::Chest wall for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/33/count/66]Anorexia for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/34/count/68]Diarrhea for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/35/count/70]Heartburn/dyspepsia for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/36/count/72]Mucositis/stomatitis (clinical exam)::Oral cavity for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/37/count/74]Nausea for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/38/count/76]Edema: limb for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/39/count/78]Fatigue (asthenia, lethargy, malaise) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/40/count/80]Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/41/count/82]Bone pain for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/42/count/84]AST, SGOT(serum glutamic oxaloacetic transaminase) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/43/count/86]Alkaline phosphatase for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/44/count/88]Bilirubin (hyperbilirubinemia) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/45/count/90]Rhinorrhea for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/46/count/92]Allergic reaction/hypersensitivity (including drug fever) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/47/count/94]Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/48/count/96]Autoimmune reaction for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/49/count/98]Febrile neutropenia for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/50/count/100]Infection w/neutropenia for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/51/count/102]Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/52/count/104]Infection with normal ANC or Grade 1 or 2 neutrophils::Upper aerodigestive NOS for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/53/count/106]Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/54/count/108]Infection with unknown ANC::Skin (cellulites) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/55/count/110]Calcium, serum-low (hypocalcemia) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/56/count/112]Glucose, serum-low (hyperglycemia) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/57/count/114]Glucose, serum-low (hypoglycemia) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/58/count/116]Magnesium, serum-high (hypermagnesemia) for NCT00001586 for E2 in NCT00001586 [clinicaltrials_resource:NCT00001586/other_events/59/count/118]
group [clinicaltrials_vocabulary:group]
Low-Intermediate Risk B-Cell Pts [clinicaltrials_resource:NCT00001586/group/E2]
Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered.
Bio2RDF identifier
NCT00001586/group/E2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00001586/group/E2
group id [clinicaltrials_vocabulary:group-id]
description
Previously untreated low or in ...... imab fludarabine administered.
@en
identifier
clinicaltrials_resource:NCT00001586/group/E2
title
Low-Intermediate Risk B-Cell Pts
@en
type
label
Low-Intermediate Risk B-Cell Pts [clinicaltrials_resource:NCT00001586/group/E2]
@en